Under the agreement, the engineering partner will be responsible for a significant portion of the software development for the Vicarious robotic system.
Vicarious inks software partnership as it streamlines operations Read More »
The US dramatically altered its recommendations for a series of vaccines, which drive billion-dollar earnings for giants like Merck and Pfizer.
Vaccine Investors Keep Their Heads Down as Trump Cuts Shot Schedule Read More »
Eli Lilly kicked off a pivotal 2026 campaign with a multi-year collaboration with current partner Nimbus Therapeutics worth a potential $1.3 billion for a preclinical obesity therapeutic. The deal follows a 2022 partnership struck by the companies to target the AMPK protein in cardiometabolic diseases.
Lilly Doubles Down with Nimbus, Paying $55M For Preclinical Obesity Drug Read More »
Arrowhead heralded the results as proof of concept that inhibiting the Activin E pathway can improve body composition and enhance weight loss as compared to tirzepatide alone, particularly in patients with type 2 diabetes.
Arrowhead Enters Obesity Chat by Doubling Tirzepatide’s Weight Loss in Combo Study Read More »
The agreement, which BMO Capital Markets called a “mild positive” for Structure, appears to address Roche’s concerns about the composition of investigational weight loss drug CT-996.
Roche Clears Obesity Pill Legal Concerns With Structure Patent Agreement Read More »
In a drastic decision made outside of its typical review process, the agency declared it would recommend 11 childhood shots going forward, down from 17.
CDC, following Trump’s orders, weakens US stance on childhood vaccinations Read More »
While Zenas’ obexelimab hit the primary endpoint in the Phase III INDIGO study, it came far below the efficacy threshold set by Amgen’s B cell depleter Uplizna, approved by the FDA for IgG4-related disease last April.
Zenas Plummets After Late-Stage Data Fall Short of Amgen in Inflammatory Disease Read More »
Last month, the FDA declined to approve Sanofi’s tolebrutinib for a specific form of multiple sclerosis. In a recently published complete response letter, the agency detailed its reasoning behind the rejection.
Sanofi’s MS Drug Tripped Up By Toxicities, Unclear Benefit, Rejection Letter Reveals Read More »
OncoNano’s platform, called ON-BOARD, packages drugs in pH-sensitive micelles that ensure their specific delivery near tumors, while also preventing systemic exposure.
Gilead Keeps Dealing With $300M OncoNano Drug Delivery Cancer Pact Read More »
Con el reciente aumento de Bitcoin hasta los $92,000, el mercado de criptomonedas se perfila para un potencial explosivo de ganancias. Sin embargo, la fuerte volatilidad que experimentó el mercado de criptomonedas en el cuarto trimestre de 2025 ha disuadido a muchos inversores, difi …
